[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100601515":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":11,"centralContacts":11,"locations":27,"responsibleParty":64,"collaborators":11,"id":67,"slug":68,"hasResults":69,"nctId":70,"briefTitle":71,"officialTitle":71,"acronym":11,"eligibilityCriteria":72,"healthyVolunteers":69,"sex":73,"minAge":74,"maxAge":11,"enrollmentInfo":75,"targetDuration":11,"studyType":78,"phases":79,"briefSummary":81,"conditions":82,"keywords":84,"overallStatus":30,"whyStopped":11,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":96},{"fullName":5,"class":6},"Medical College of Wisconsin","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"GLP-1","ACTIVE_COMPARATOR",null,[13],"Drug: GLP-1 agonists",{"label":15,"type":10,"description":11,"interventionNames":16},"Nutrition Counseling",[17],"Other: Nutrition Counseling",[19,24],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":11},"DRUG","GLP-1 agonists","GLP-1, any assigned drug",[9],{"type":6,"name":15,"description":25,"armGroupLabels":26,"otherNames":11},"Nutrition Counseling in PsA",[15],[28],{"facility":29,"status":30,"city":31,"state":32,"zip":33,"country":34,"countryCode":35,"cosmosGeoPoint":36,"geoPoint":41,"contacts":42},"Medical College of Wisconsin\u002FFroedtert Hosptial","RECRUITING","Milwaukee","Wisconsin","53226","United States","US",{"type":37,"coordinates":38},"Point",[39,40],-87.90647,43.0389,{"lat":40,"lon":39},[43,48,51,53,56,58,60,62],{"name":44,"role":45,"phone":46,"phoneExt":11,"email":47},"Shikha Singla, MD","CONTACT","414-955-7040","ssingla@mcw.edu",{"name":49,"role":45,"phone":11,"phoneExt":11,"email":50},"Kiley Timler","ktimler@mcw.edu",{"name":44,"role":52,"phone":11,"phoneExt":11,"email":11},"PRINCIPAL_INVESTIGATOR",{"name":54,"role":55,"phone":11,"phoneExt":11,"email":11},"David Gazeley, MD","SUB_INVESTIGATOR",{"name":57,"role":55,"phone":11,"phoneExt":11,"email":11},"Michael Putman, MD",{"name":59,"role":55,"phone":11,"phoneExt":11,"email":11},"Lisa Morseli, MD",{"name":61,"role":55,"phone":11,"phoneExt":11,"email":11},"Ann Rosenthal, MD",{"name":63,"role":55,"phone":11,"phoneExt":11,"email":11},"Anam Qureshi, MD",{"type":52,"investigatorFullName":65,"investigatorTitle":66,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"David Gazeley","Associate Professor","100601515","impact-of-glucagon-like-peptide-1-glp-1-analogs-on-disease-outcomes-in-psoriatic-arthritis-a-pragmatic-randomized-controlled-trial-100601515",false,"NCT07111494","Impact of Glucagon-like Peptide-1 (GLP-1) Analogs on Disease Outcomes in Psoriatic Arthritis: A Pragmatic Randomized Controlled Trial","Inclusion Criteria:\n\n* Adult patients (age 18 and older) who present to rheumatology clinic\n* Participants must be able to read, understand, and provide documented informed consent as approved by the Institutional Review Board (IRB).\n* Meet the Classification of Psoriatic Arthritis (CASPAR) criteria for PsA\n* Participants must have a Body Mass Index (BMI) of 30kg\u002Fm\\^2\n* Participants must be treated for PsA in accordance with guidelines\n* Have not achieved MDA in PsA patients\n* Have a minimum TJC \\> 1 and SJC \\> at baseline\n* Eligible for GLP-1 agonist treatment in accordance with Food Drug Administration (FDA) labeling as determined by the investigator.\n\nExclusion Criteria:\n\n* Any prior use of GLP-1 agonists\n* Inability to provide informed consent\n* Current participation in another PsA study\n* Treatment initiation by GLP-1 agonists contraindicated by FDA\n* Patients with hemoglobin A1c (HbA1c) \\> 10 at baseline","ALL","18 Years",{"count":76,"type":77},22,"ESTIMATED","INTERVENTIONAL",[80],"PHASE4","Psoriatic arthritis (PsA) is a chronic inflammatory condition that affects the joints but can also have an effect on multiple parts of the body. This study will assess if the effectiveness of Glucagon-like peptide-1 (GLP-1) medications used to treat type 2-diabetes and weight management, or nutrition counseling can better treat individuals with Psoriatic Arthritis who are also needing treatment for obesity and type 2 diabetes.\n\nThe main objectives it aims to answer are:\n\nTo assess disease outcomes of PsA patients undergoing treatment for concomitant obesity and type 2 diabetes with GLP-1 analogs vs nutrition counseling.\n\nTo assess effectiveness as measured by clinical and patient reported outcome measures in patients treated with GLP-1 and nutrition counseling.\n\nParticipants will be randomized to receive a GLP-1 or nutrition counseling. Participants will be asked to come to the study center at most four times during a 24-week period. During this time participants will be asked to fill out questionnaires, receive a physical exam, and have their blood drawn.",[83],"Psoriatic Arthritis (PsA)",[85,9,86,15],"Psoriatic Arthritis","Minimal Disease Activity","2026-08-05",{"date":89,"type":90},"2026-08-10","ACTUAL",{"date":92,"type":90},"2026-05-01",{"date":94,"type":77},"2028-10-15",{"name":5,"class":6},1]